APO Research
Talk to an analyst

APO RESEARCH · REPORT

Osteoporosis Drugs

Osteoporosis is a disease where decreased bone strength increases the risk of a broken bone. It is the most common reason for a broken bone among the elderly. Bones that commonly break include the back bones, the bones of the forearm, and the hip. Until a broken bone occurs there are typically no symptoms. Bones may weaken to such a degree that a break may occur with minor stress or spontaneously. Chronic pain and a decreased ability to carry out normal activities may occur following a broken bone.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Osteoporosis is a disease where decreased bone strength increases the risk of a broken bone. It is the most common reason for a broken bone among the elderly. Bones that commonly break include the back bones, the bones of the forearm, and the hip. Until a broken bone occurs there are typically no symptoms. Bones may weaken to such a degree that a break may occur with minor stress or spontaneously. Chronic pain and a decreased ability to carry out normal activities may occur following a broken bone.

Osteoporosis may be due to lower than normal peak bone mass and greater than normal bone loss. Bone loss increases after menopause due to lower levels of estrogen. Osteoporosis may also occur due to a number of diseases or treatments including alcoholism, anorexia, hyperthyroidism, surgical removal of the ovaries, and kidney disease. Certain medications increase the rate of bone loss including some antiseizure medications, chemotherapy, proton pump inhibitors, selective serotonin reuptake inhibitors, and steroids. Not enough exercise and smoking are also risk factors. Osteoporosis is defined as a bone density of 2.5 standard deviations below that of a young adult. This is typically measured by dual-energy X-ray absorptiometry at the hip.

Selected research

Industry Growth & Trends

Global Osteoporosis Drugs Industry Growth and Trends Forecast to 2032

20 December 202594 pages

Choose your research edition.

Industry ResearchOsteoporosis Drugs Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Osteoporosis Drugs Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal Osteoporosis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Osteoporosis Drugs Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Osteoporosis Drugs Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

Osteoporosis is a disease where decreased bone strength increases the risk of a broken bone. It is the most common reason for a broken bone among the elderly. Bones that commonly break include the back bones, the bones of the forearm, and the hip. Until a broken bone occurs there are typically no symptoms. Bones may weaken to such a degree that a break may occur with minor stress or spontaneously. Chronic pain and a decreased ability to carry out normal activities may occur following a broken bone.

Osteoporosis may be due to lower than normal peak bone mass and greater than normal bone loss. Bone loss increases after menopause due to lower levels of estrogen. Osteoporosis may also occur due to a number of diseases or treatments including alcoholism, anorexia, hyperthyroidism, surgical removal of the ovaries, and kidney disease. Certain medications increase the rate of bone loss including some antiseizure medications, chemotherapy, proton pump inhibitors, selective serotonin reuptake inhibitors, and steroids. Not enough exercise and smoking are also risk factors. Osteoporosis is defined as a bone density of 2.5 standard deviations below that of a young adult. This is typically measured by dual-energy X-ray absorptiometry at the hip.

In Brazil, Osteoporosis Drugs key players include Eli Lilly, Novartis, Pfizer, etc. Global top three manufacturers hold a share over 35%.

Read the full market overview

In terms of product, Antiresorptive Drugs is the largest segment, with a share over 70%. And in terms of application, the largest application is Female, followed by Male.

Report Scope

This report provides a structured, data-driven view of the global Osteoporosis Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Osteoporosis Drugs market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Osteoporosis Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Osteoporosis Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Osteoporosis Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Osteoporosis Drugs Market by Company

Eli Lilly

Novartis

Pfizer

Amgen

Merck

Novo nordisk

Actavis

Roche

Osteoporosis Drugs Segment by Type

Antiresorptive Drugs

Anabolic Drugs

Osteoporosis Drugs Segment by Application

Female

Male

Osteoporosis Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Osteoporosis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Osteoporosis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Osteoporosis Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Osteoporosis Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Osteoporosis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Antiresorptive Drugs Table 2. Major Company of Anabolic Drugs Table 3. Global Osteoporosis Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Osteoporosis Drugs Sales by Type (2021-2026) & (K Units) Table 5. Global Osteoporosis Drugs Sales Market Share in Volume by Type (2021-2026) Table 6. Global Osteoporosis Drugs Sales by Type (2021-2026) & (US$ Million) Table 7. Global Osteoporosis Drugs Sales Market Share in Value by Type (2021-2026) Table 8. Global Osteoporosis Drugs Price by Type (2021-2026) & (USD/Unit) Table 9. Global Osteoporosis Drugs Sales by Type (2027-2032) & (K Units) Table 10. Global Osteoporosis Drugs Sales Market Share in Volume by Type (2027-2032) Table 11. Global Osteoporosis Drugs Sales by Type (2027-2032) & (US$ Million) Table 12. Global Osteoporosis Drugs Sales Market Share in Value by Type (2027-2032) Table 13. Global Osteoporosis Drugs Price by Type (2027-2032) & (USD/Unit) Table 14. North America Osteoporosis Drugs Sales by Type (2021-2026) & (K Units) Table 15. North America Osteoporosis Drugs Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Osteoporosis Drugs Sales by Type (2021-2026) & (K Units) Table 17. Europe Osteoporosis Drugs Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Osteoporosis Drugs Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Osteoporosis Drugs Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Osteoporosis Drugs Sales by Type (2021-2026) & (K Units) Table 21. Latin America Osteoporosis Drugs Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Osteoporosis Drugs Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Osteoporosis Drugs Sales by Type (2021-2026) & (US$ Million) Table 24. Osteoporosis Drugs Industry Trends Table 25. Osteoporosis Drugs Industry Drivers Table 26. Osteoporosis Drugs Industry Opportunities and Challenges Table 27. Osteoporosis Drugs Industry Restraints Table 28. Global Osteoporosis Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Osteoporosis Drugs Revenue Market Share by Company (2021-2026) Table 30. Global Osteoporosis Drugs Sales by Company (2021-2026) & (K Units) Table 31. Global Osteoporosis Drugs Sales Share by Company (2021-2026) Table 32. Global Osteoporosis Drugs Market Price by Company (2021-2026) & (USD/Unit) Table 33. Global Osteoporosis Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Osteoporosis Drugs Major Company Production Sites and Headquarters Table 35. Global Osteoporosis Drugs Company, Product Type & Application Table 36. Global Osteoporosis Drugs Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Osteoporosis Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Osteoporosis Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Osteoporosis Drugs Sales by Region (2021-2026) & (K Units) Table 41. Global Osteoporosis Drugs Sales Market Share in Volume by Region (2021-2026) Table 42. Global Osteoporosis Drugs Sales by Region (2021-2026) & (US$ Million) Table 43. Global Osteoporosis Drugs Sales Market Share in Value by Region (2021-2026) Table 44. Global Osteoporosis Drugs Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 45. Global Osteoporosis Drugs Sales by Region (2027-2032) & (K Units) Table 46. Global Osteoporosis Drugs Sales Market Share in Volume by Region (2027-2032) Table 47. Global Osteoporosis Drugs Sales by Region (2027-2032) & (US$ Million) Table 48. Global Osteoporosis Drugs Sales Market Share in Value by Region (2027-2032) Table 49. Global Osteoporosis Drugs Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2027-2032) Table 50. Global Osteoporosis Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Osteoporosis Drugs Sales by Application (2021-2026) & (K Units) Table 52. Global Osteoporosis Drugs Sales Market Share in Volume by Application (2021-2026) Table 53. Global Osteoporosis Drugs Sales by Application (2021-2026) & (US$ Million) Table 54. Global Osteoporosis Drugs Sales Market Share in Value by Application (2021-2026) Table 55. Global Osteoporosis Drugs Price by Application (2021-2026) & (USD/Unit) Table 56. Global Osteoporosis Drugs Sales by Application (2027-2032) & (K Units) Table 57. Global Osteoporosis Drugs Sales Market Share in Volume by Application (2027-2032) Table 58. Global Osteoporosis Drugs Sales by Application (2027-2032) & (US$ Million) Table 59. Global Osteoporosis Drugs Sales Market Share in Value by Application (2027-2032) Table 60. Global Osteoporosis Drugs Price by Application (2027-2032) & (USD/Unit) Table 61. North America Osteoporosis Drugs Sales by Application (2021-2026) & (K Units) Table 62. North America Osteoporosis Drugs Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Osteoporosis Drugs Sales by Application (2021-2026) & (K Units) Table 64. Europe Osteoporosis Drugs Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Osteoporosis Drugs Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Osteoporosis Drugs Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Osteoporosis Drugs Sales by Application (2021-2026) & (K Units) Table 68. Latin America Osteoporosis Drugs Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Osteoporosis Drugs Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Osteoporosis Drugs Sales by Application (2021-2026) & (US$ Million) Table 71. Eli Lilly Company Information Table 72. Eli Lilly Business Overview Table 73. Eli Lilly Osteoporosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 74. Eli Lilly Osteoporosis Drugs Product Portfolio Table 75. Eli Lilly Recent Development Table 76. Novartis Company Information Table 77. Novartis Business Overview Table 78. Novartis Osteoporosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 79. Novartis Osteoporosis Drugs Product Portfolio Table 80. Novartis Recent Development Table 81. Pfizer Company Information Table 82. Pfizer Business Overview Table 83. Pfizer Osteoporosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 84. Pfizer Osteoporosis Drugs Product Portfolio Table 85. Pfizer Recent Development Table 86. Amgen Company Information Table 87. Amgen Business Overview Table 88. Amgen Osteoporosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 89. Amgen Osteoporosis Drugs Product Portfolio Table 90. Amgen Recent Development Table 91. Merck Company Information Table 92. Merck Business Overview Table 93. Merck Osteoporosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 94. Merck Osteoporosis Drugs Product Portfolio Table 95. Merck Recent Development Table 96. Novo nordisk Company Information Table 97. Novo nordisk Business Overview Table 98. Novo nordisk Osteoporosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 99. Novo nordisk Osteoporosis Drugs Product Portfolio Table 100. Novo nordisk Recent Development Table 101. Actavis Company Information Table 102. Actavis Business Overview Table 103. Actavis Osteoporosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 104. Actavis Osteoporosis Drugs Product Portfolio Table 105. Actavis Recent Development Table 106. Roche Company Information Table 107. Roche Business Overview Table 108. Roche Osteoporosis Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 109. Roche Osteoporosis Drugs Product Portfolio Table 110. Roche Recent Development Table 111. North America Osteoporosis Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 112. North America Osteoporosis Drugs Sales by Country (2021-2026) & (K Units) Table 113. North America Osteoporosis Drugs Sales Market Share by Country (2021-2026) Table 114. North America Osteoporosis Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 115. North America Osteoporosis Drugs Sales Market Share Forecast by Country (2027-2032) Table 116. North America Osteoporosis Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 117. North America Osteoporosis Drugs Market Size by Country (2021-2026) & (US$ Million) Table 118. North America Osteoporosis Drugs Market Share by Country (2021-2026) Table 119. North America Osteoporosis Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 120. North America Osteoporosis Drugs Market Share Forecast by Country (2027-2032) Table 121. Europe Osteoporosis Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 122. Europe Osteoporosis Drugs Sales by Country (2021-2026) & (K Units) Table 123. Europe Osteoporosis Drugs Sales Market Share by Country (2021-2026) Table 124. Europe Osteoporosis Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 125. Europe Osteoporosis Drugs Sales Market Share Forecast by Country (2027-2032) Table 126. Europe Osteoporosis Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 127. Europe Osteoporosis Drugs Market Size by Country (2021-2026) & (US$ Million) Table 128. Europe Osteoporosis Drugs Market Share by Country (2021-2026) Table 129. Europe Osteoporosis Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 130. Europe Osteoporosis Drugs Market Share Forecast by Country (2027-2032) Table 131. Asia-Pacific Osteoporosis Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 132. Asia-Pacific Osteoporosis Drugs Sales by Country (2021-2026) & (K Units) Table 133. Asia-Pacific Osteoporosis Drugs Sales Market Share by Country (2021-2026) Table 134. Asia-Pacific Osteoporosis Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 135. Asia-Pacific Osteoporosis Drugs Sales Market Share Forecast by Country (2027-2032) Table 136. Asia-Pacific Osteoporosis Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 137. Asia-Pacific Osteoporosis Drugs Market Size by Country (2021-2026) & (US$ Million) Table 138. Asia-Pacific Osteoporosis Drugs Market Share by Country (2021-2026) Table 139. Asia-Pacific Osteoporosis Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 140. Asia-Pacific Osteoporosis Drugs Market Share Forecast by Country (2027-2032) Table 141. Latin America Osteoporosis Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 142. Latin America Osteoporosis Drugs Sales by Country (2021-2026) & (K Units) Table 143. Latin America Osteoporosis Drugs Sales Market Share by Country (2021-2026) Table 144. Latin America Osteoporosis Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 145. Latin America Osteoporosis Drugs Sales Market Share Forecast by Country (2027-2032) Table 146. Latin America Osteoporosis Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 147. Latin America Osteoporosis Drugs Market Size by Country (2021-2026) & (US$ Million) Table 148. Latin America Osteoporosis Drugs Market Share by Country (2021-2026) Table 149. Latin America Osteoporosis Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 150. Latin America Osteoporosis Drugs Market Share Forecast by Country (2027-2032) Table 151. Middle East and Africa Osteoporosis Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 152. Middle East and Africa Osteoporosis Drugs Sales by Country (2021-2026) & (K Units) Table 153. Middle East and Africa Osteoporosis Drugs Sales Market Share by Country (2021-2026) Table 154. Middle East and Africa Osteoporosis Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 155. Middle East and Africa Osteoporosis Drugs Sales Market Share Forecast by Country (2027-2032) Table 156. Middle East and Africa Osteoporosis Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 157. Middle East and Africa Osteoporosis Drugs Market Size by Country (2021-2026) & (US$ Million) Table 158. Middle East and Africa Osteoporosis Drugs Market Share by Country (2021-2026) Table 159. Middle East and Africa Osteoporosis Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 160. Middle East and Africa Osteoporosis Drugs Market Share Forecast by Country (2027-2032) Table 161. Key Raw Materials Table 162. Raw Materials Key Suppliers Table 163. Osteoporosis Drugs Distributors List Table 164. Osteoporosis Drugs Customers List Table 165. Research Programs/Design for This Report Table 166. Authors List of This Report Table 167. Secondary Sources Table 168. Primary Sources List of Figures Figure 1. Osteoporosis Drugs Image Figure 2. Global Osteoporosis Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Osteoporosis Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Osteoporosis Drugs Sales (2021-2032) & (K Units) Figure 5. Antiresorptive Drugs Image Figure 6. Global Antiresorptive Drugs Sales YoY Growth (2021-2032) & (K Units) Figure 7. Anabolic Drugs Image Figure 8. Global Anabolic Drugs Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Osteoporosis Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Osteoporosis Drugs Market Share by Type 2025 VS 2032 Figure 11. North America Osteoporosis Drugs Sales Market Share in Volume by Type in 2025 Figure 12. North America Osteoporosis Drugs Sales Market Share in Value by Type in 2025 Figure 13. Europe Osteoporosis Drugs Sales Market Share in Volume by Type in 2025 Figure 14. Europe Osteoporosis Drugs Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Osteoporosis Drugs Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Osteoporosis Drugs Sales Market Share in Value by Type in 2025 Figure 17. Latin America Osteoporosis Drugs Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Osteoporosis Drugs Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Osteoporosis Drugs Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Osteoporosis Drugs Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Osteoporosis Drugs Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Female Image Figure 24. Global Female Sales YoY Growth (2021-2032) & (K Units) Figure 25. Male Image Figure 26. Global Male Sales YoY Growth (2021-2032) & (K Units) Figure 27. Global Osteoporosis Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 28. Global Osteoporosis Drugs Market Share by Application 2025 VS 2032 Figure 29. North America Osteoporosis Drugs Sales Market Share in Volume by Application in 2025 Figure 30. North America Osteoporosis Drugs Sales Market Share in Value by Application in 2025 Figure 31. Europe Osteoporosis Drugs Sales Market Share in Volume by Application in 2025 Figure 32. Europe Osteoporosis Drugs Sales Market Share in Value by Application in 2025 Figure 33. Asia-Pacific Osteoporosis Drugs Sales Market Share in Volume by Application in 2025 Figure 34. Asia-Pacific Osteoporosis Drugs Sales Market Share in Value by Application in 2025 Figure 35. Latin America Osteoporosis Drugs Sales Market Share in Volume by Application in 2025 Figure 36. Latin America Osteoporosis Drugs Sales Market Share in Value by Application in 2025 Figure 37. Middle East and Africa Osteoporosis Drugs Sales Market Share in Volume by Application in 2025 Figure 38. Middle East and Africa Osteoporosis Drugs Sales Market Share in Value by Application in 2025 Figure 39. North America Osteoporosis Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 40. North America Osteoporosis Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 41. North America Osteoporosis Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 42. North America Osteoporosis Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 43. Europe Osteoporosis Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 44. Europe Osteoporosis Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Osteoporosis Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. Europe Osteoporosis Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Asia-Pacific Osteoporosis Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. Asia-Pacific Osteoporosis Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Osteoporosis Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Asia-Pacific Osteoporosis Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Latin America Osteoporosis Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Latin America Osteoporosis Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Osteoporosis Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Latin America Osteoporosis Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Middle East and Africa Osteoporosis Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Middle East and Africa Osteoporosis Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Osteoporosis Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Middle East and Africa Osteoporosis Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Osteoporosis Drugs Value Chain Figure 60. Key Raw Materials Price Figure 61. Manufacturing Cost Structure Figure 62. Osteoporosis Drugs Production Mode & Process Figure 63. Direct Comparison with Distribution Share Figure 64. Distributors Profiles Figure 65. Years Considered Figure 66. Research Process Figure 67. Key Executives Interviewed

Scope & coverage.

Types
  • Antiresorptive Drugs
  • Anabolic Drugs
Applications
  • Female
  • Male
Companies covered
  • Eli Lilly
  • Novartis
  • Pfizer
  • Amgen
  • Merck
  • Novo nordisk
  • Actavis
  • Roche

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Osteoporosis Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Osteoporosis Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Osteoporosis Drugs Market by Type
  6. 1.3.1 Antiresorptive Drugs
  7. 1.3.2 Anabolic Drugs
  8. 1.4 Global Osteoporosis Drugs Market Size by Type
  9. 1.4.1 Global Osteoporosis Drugs Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Osteoporosis Drugs Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Osteoporosis Drugs Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Osteoporosis Drugs Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Osteoporosis Drugs Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Osteoporosis Drugs Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Osteoporosis Drugs Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Osteoporosis Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Osteoporosis Drugs Industry Trends
  2. 2.2 Osteoporosis Drugs Industry Drivers
  3. 2.3 Osteoporosis Drugs Industry Opportunities and Challenges
  4. 2.4 Osteoporosis Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Osteoporosis Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by Osteoporosis Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by Osteoporosis Drugs Price (2021-2026)
  4. 3.4 Global Osteoporosis Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Osteoporosis Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global Osteoporosis Drugs Company, Product Type & Application
  7. 3.7 Global Osteoporosis Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Osteoporosis Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Osteoporosis Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Osteoporosis Drugs Tier 1, Tier 2, and Tier 3
4 Osteoporosis Drugs Regional Status and Outlook
  1. 4.1 Global Osteoporosis Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Osteoporosis Drugs Historic Market Size by Region
  3. 4.2.1 Global Osteoporosis Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Osteoporosis Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Osteoporosis Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Osteoporosis Drugs Forecasted Market Size by Region
  7. 4.3.1 Global Osteoporosis Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Osteoporosis Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Osteoporosis Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Osteoporosis Drugs by Application
  1. 5.1 Osteoporosis Drugs Market by Application
  2. 5.1.1 Female
  3. 5.1.2 Male
  4. 5.2 Global Osteoporosis Drugs Market Size by Application
  5. 5.2.1 Global Osteoporosis Drugs Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global Osteoporosis Drugs Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global Osteoporosis Drugs Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America Osteoporosis Drugs Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe Osteoporosis Drugs Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific Osteoporosis Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America Osteoporosis Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa Osteoporosis Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Eli Lilly
  2. 6.1.1 Eli Lilly Company Information
  3. 6.1.2 Eli Lilly Business Overview
  4. 6.1.3 Eli Lilly Osteoporosis Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Eli Lilly Osteoporosis Drugs Product Portfolio
  6. 6.1.5 Eli Lilly Recent Developments
  7. 6.2 Novartis
  8. 6.2.1 Novartis Company Information
  9. 6.2.2 Novartis Business Overview
  10. 6.2.3 Novartis Osteoporosis Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Novartis Osteoporosis Drugs Product Portfolio
  12. 6.2.5 Novartis Recent Developments
  13. 6.3 Pfizer
  14. 6.3.1 Pfizer Company Information
  15. 6.3.2 Pfizer Business Overview
  16. 6.3.3 Pfizer Osteoporosis Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Pfizer Osteoporosis Drugs Product Portfolio
  18. 6.3.5 Pfizer Recent Developments
  19. 6.4 Amgen
  20. 6.4.1 Amgen Company Information
  21. 6.4.2 Amgen Business Overview
  22. 6.4.3 Amgen Osteoporosis Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Amgen Osteoporosis Drugs Product Portfolio
  24. 6.4.5 Amgen Recent Developments
  25. 6.5 Merck
  26. 6.5.1 Merck Company Information
  27. 6.5.2 Merck Business Overview
  28. 6.5.3 Merck Osteoporosis Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Merck Osteoporosis Drugs Product Portfolio
  30. 6.5.5 Merck Recent Developments
  31. 6.6 Novo nordisk
  32. 6.6.1 Novo nordisk Company Information
  33. 6.6.2 Novo nordisk Business Overview
  34. 6.6.3 Novo nordisk Osteoporosis Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Novo nordisk Osteoporosis Drugs Product Portfolio
  36. 6.6.5 Novo nordisk Recent Developments
  37. 6.7 Actavis
  38. 6.7.1 Actavis Company Information
  39. 6.7.2 Actavis Business Overview
  40. 6.7.3 Actavis Osteoporosis Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Actavis Osteoporosis Drugs Product Portfolio
  42. 6.7.5 Actavis Recent Developments
  43. 6.8 Roche
  44. 6.8.1 Roche Company Information
  45. 6.8.2 Roche Business Overview
  46. 6.8.3 Roche Osteoporosis Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Roche Osteoporosis Drugs Product Portfolio
  48. 6.8.5 Roche Recent Developments
7 North America by Country
  1. 7.1 North America Osteoporosis Drugs Sales by Country
  2. 7.1.1 North America Osteoporosis Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Osteoporosis Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America Osteoporosis Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Osteoporosis Drugs Market Size by Country
  6. 7.2.1 North America Osteoporosis Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Osteoporosis Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America Osteoporosis Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Osteoporosis Drugs Sales by Country
  2. 8.1.1 Europe Osteoporosis Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Osteoporosis Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe Osteoporosis Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Osteoporosis Drugs Market Size by Country
  6. 8.2.1 Europe Osteoporosis Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Osteoporosis Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Osteoporosis Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Osteoporosis Drugs Sales by Country
  2. 9.1.1 Asia-Pacific Osteoporosis Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Osteoporosis Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Osteoporosis Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Osteoporosis Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific Osteoporosis Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Osteoporosis Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Osteoporosis Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Osteoporosis Drugs Sales by Country
  2. 10.1.1 South America Osteoporosis Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Osteoporosis Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America Osteoporosis Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Osteoporosis Drugs Market Size by Country
  6. 10.2.1 South America Osteoporosis Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Osteoporosis Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America Osteoporosis Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Osteoporosis Drugs Sales by Country
  2. 11.1.1 Middle East and Africa Osteoporosis Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Osteoporosis Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Osteoporosis Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Osteoporosis Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa Osteoporosis Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Osteoporosis Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Osteoporosis Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Osteoporosis Drugs Value Chain Analysis
  2. 12.1.1 Osteoporosis Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Osteoporosis Drugs Production Mode & Process
  7. 12.2 Osteoporosis Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Osteoporosis Drugs Distributors
  10. 12.2.3 Osteoporosis Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst